A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a b...
Saved in:
Published in | BMC urology Vol. 17; no. 1; p. 63 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
22.08.2017
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC).
We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m
on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m
every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m
biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline.
The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups.
Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC. |
---|---|
AbstractList | The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m.sup.2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m.sup.2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m.sup.2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC. The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC. Background The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). Methods We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m.sup.2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m.sup.2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m.sup.2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. Results The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Conclusions Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC. Keywords: Castrate-resistant prostate cancer, Docetaxel, Biweekly BACKGROUNDThe aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC).METHODSWe retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline.RESULTSThe baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups.CONCLUSIONSWithin the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC. Background The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). Methods We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naive patients with CRPC received a 40 mg/m2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. Results The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Conclusions Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC. |
ArticleNumber | 63 |
Audience | Academic |
Author | Jeong, Byong Chang Jeon, Seong Soo Lee, Ji Yun Sung, Hyun Hwan Seo, Seong Il Lee, Hyun Moo Choi, Han-Yong Kim, Hae Su Lee, Su Jin Lim, Ho Yeong Jeon, Hwang Gyun Park, Se Hoon |
Author_xml | – sequence: 1 givenname: Hae Su surname: Kim fullname: Kim, Hae Su organization: Department of Hematology-Oncology, Department of Medicine, Veterans Health Service Medical Center, Seoul, South Korea – sequence: 2 givenname: Ji Yun surname: Lee fullname: Lee, Ji Yun organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 135-710, South Korea – sequence: 3 givenname: Su Jin surname: Lee fullname: Lee, Su Jin organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 135-710, South Korea – sequence: 4 givenname: Ho Yeong surname: Lim fullname: Lim, Ho Yeong organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 135-710, South Korea – sequence: 5 givenname: Hyun Hwan surname: Sung fullname: Sung, Hyun Hwan organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 6 givenname: Hwang Gyun surname: Jeon fullname: Jeon, Hwang Gyun organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 7 givenname: Byong Chang surname: Jeong fullname: Jeong, Byong Chang organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 8 givenname: Seong Il surname: Seo fullname: Seo, Seong Il organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 9 givenname: Seong Soo surname: Jeon fullname: Jeon, Seong Soo organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 10 givenname: Hyun Moo surname: Lee fullname: Lee, Hyun Moo organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 11 givenname: Han-Yong surname: Choi fullname: Choi, Han-Yong organization: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 12 givenname: Se Hoon orcidid: 0000-0001-5084-9326 surname: Park fullname: Park, Se Hoon email: hematoma@skku.edu organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 135-710, South Korea. hematoma@skku.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28830482$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk1vFSEUhiemxn7oD3BjSNy46FQ-Z5iNyU2jrUkTN7omDBxa6gxcgWm9_Qv-abm5tbbGsOAEnvc9HPIeNnshBmia1wSfECK795lQOfAWk77FVLD27llzQHhPWsoHvPeo3m8Oc77GFZSie9HsUykZ5pIeNL9WKEFJMa_BFH8DyIHOfvSTLxuUy2I3KDo0-luA79PmuMJ2MWBbGzMgGw0U_RMm5ANaZa8DWuviIZSMbn25QkbnknSBNkH2uehQjtFcJbUs3qB17VsrqFwwkF42z52eMry634-ab58-fj09by--nH0-XV20hg-8tNwyRyVm0hGBJXSCwqCx5b0dBSXO4Y71dehOOGt6KqwdGKNu5AN0vSRWs6Pmw853vYwzWFPfm_Sk1snPOm1U1F49vQn-Sl3GGyVE1w-YVIN39wYp_lggFzX7bGCadIC4ZEUGRnrSSSYr-vYf9DouKdTxthTvBO8G_pe61BMoH1ysfc3WVK0EIbQnYhCVOvkPVZeF2ZsaDefr-RMB2QlM_eicwD3MSLDaJkjtEqRqMNQ2Qequat48_pwHxZ_IsN_MtsVp |
CitedBy_id | crossref_primary_10_1080_07357907_2020_1871486 crossref_primary_10_1097_MD_0000000000019931 crossref_primary_10_1186_s12885_021_09018_6 crossref_primary_10_1186_s12894_019_0463_7 crossref_primary_10_1093_jncics_pkaa003 crossref_primary_10_1016_j_esmoop_2023_101194 crossref_primary_10_1016_j_clgc_2022_02_009 |
Cites_doi | 10.4143/crt.2010.42.1.12 10.1056/NEJMoa041318 10.1016/j.eururo.2007.03.072 10.1200/JCO.2007.12.4008 10.3816/CGC.2003.n.012 10.1016/S1470-2045(14)70018-X 10.1200/JCO.1985.3.6.827 10.1093/jjco/hym071 10.1016/S0140-6736(10)61389-X 10.1056/NEJMoa1503747 10.1016/S1470-2045(12)70537-5 10.1016/S1470-2045(12)70560-0 10.1056/NEJMoa040720 10.1002/cncr.22446 10.4143/crt.2015.060 10.1056/NEJMoa1209096 10.1016/S0140-6736(08)60729-1 10.1200/JCO.2007.12.4487 10.1056/NEJMoa1213755 10.1126/science.1168175 10.1056/NEJMoa1001294 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1186/s12894-017-0253-z |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2490 |
EndPage | 63 |
ExternalDocumentID | A511271595 10_1186_s12894_017_0253_z 28830482 |
Genre | Journal Article |
GeographicLocations | South Korea |
GeographicLocations_xml | – name: South Korea |
GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EJD EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION ABVAZ AFGXO AFNRJ 7QP 7XB 8FK AHSBF AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c494t-4d3f28038f1508e652e9a0d47db521ff063724965fdc725dd9332fb49e6781da3 |
IEDL.DBID | RPM |
ISSN | 1471-2490 |
IngestDate | Tue Sep 17 20:44:01 EDT 2024 Sat Aug 17 04:57:22 EDT 2024 Thu Oct 10 16:12:23 EDT 2024 Fri Feb 23 00:14:48 EST 2024 Wed Jan 10 03:49:19 EST 2024 Thu Sep 12 17:55:51 EDT 2024 Fri Oct 18 09:22:38 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Biweekly Docetaxel Castrate-resistant prostate cancer |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c494t-4d3f28038f1508e652e9a0d47db521ff063724965fdc725dd9332fb49e6781da3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-5084-9326 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567901/ |
PMID | 28830482 |
PQID | 1934654694 |
PQPubID | 42551 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5567901 proquest_miscellaneous_1931716838 proquest_journals_1934654694 gale_infotracmisc_A511271595 gale_infotracacademiconefile_A511271595 crossref_primary_10_1186_s12894_017_0253_z pubmed_primary_28830482 |
PublicationCentury | 2000 |
PublicationDate | 2017-08-22 |
PublicationDateYYYYMMDD | 2017-08-22 |
PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-22 day: 22 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC urology |
PublicationTitleAlternate | BMC Urol |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | DP Petrylak (253_CR4) 2004; 351 G Gravis (253_CR18) 2013; 14 253_CR19 JE Damber (253_CR2) 2008; 371 A Bamias (253_CR20) 2008; 53 SH Park (253_CR9) 2007; 109 T Taguchi (253_CR8) 1994; 21 PL Kellokumpu-Lehtinen (253_CR11) 2013; 14 IF Tannock (253_CR5) 2004; 351 MA Eisenberger (253_CR3) 1985; 3 HI Scher (253_CR12) 2008; 26 PW Kantoff (253_CR17) 2010; 363 DR Berthold (253_CR6) 2008; 26 CJ Ryan (253_CR14) 2013; 368 C Parker (253_CR16) 2013; 369 JL Lee (253_CR7) 2010; 42 KW Jung (253_CR1) 2015; 47 T Shimazui (253_CR10) 2007; 37 JP Droz (253_CR22) 2014; 15 JS Bono de (253_CR13) 2010; 376 C Tran (253_CR15) 2009; 324 V Karavasilis (253_CR21) 2003; 2 |
References_xml | – volume: 42 start-page: 12 year: 2010 ident: 253_CR7 publication-title: Cancer Res Treat doi: 10.4143/crt.2010.42.1.12 contributor: fullname: JL Lee – volume: 351 start-page: 1513 year: 2004 ident: 253_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa041318 contributor: fullname: DP Petrylak – volume: 53 start-page: 323 year: 2008 ident: 253_CR20 publication-title: Eur Urol doi: 10.1016/j.eururo.2007.03.072 contributor: fullname: A Bamias – volume: 26 start-page: 242 year: 2008 ident: 253_CR6 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.4008 contributor: fullname: DR Berthold – volume: 2 start-page: 46 year: 2003 ident: 253_CR21 publication-title: Clin Prostate Cancer doi: 10.3816/CGC.2003.n.012 contributor: fullname: V Karavasilis – volume: 15 start-page: e404 year: 2014 ident: 253_CR22 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)70018-X contributor: fullname: JP Droz – volume: 3 start-page: 827 year: 1985 ident: 253_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.1985.3.6.827 contributor: fullname: MA Eisenberger – volume: 37 start-page: 603 year: 2007 ident: 253_CR10 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hym071 contributor: fullname: T Shimazui – volume: 376 start-page: 1147 year: 2010 ident: 253_CR13 publication-title: Lancet doi: 10.1016/S0140-6736(10)61389-X contributor: fullname: JS Bono de – ident: 253_CR19 doi: 10.1056/NEJMoa1503747 – volume: 14 start-page: 117 year: 2013 ident: 253_CR11 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70537-5 contributor: fullname: PL Kellokumpu-Lehtinen – volume: 21 start-page: 1997 year: 1994 ident: 253_CR8 publication-title: Gan To Kagaku Ryoho contributor: fullname: T Taguchi – volume: 14 start-page: 149 year: 2013 ident: 253_CR18 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70560-0 contributor: fullname: G Gravis – volume: 351 start-page: 1502 year: 2004 ident: 253_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa040720 contributor: fullname: IF Tannock – volume: 109 start-page: 732 year: 2007 ident: 253_CR9 publication-title: Cancer doi: 10.1002/cncr.22446 contributor: fullname: SH Park – volume: 47 start-page: 127 year: 2015 ident: 253_CR1 publication-title: Cancer Res Treat doi: 10.4143/crt.2015.060 contributor: fullname: KW Jung – volume: 368 start-page: 138 year: 2013 ident: 253_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa1209096 contributor: fullname: CJ Ryan – volume: 371 start-page: 1710 year: 2008 ident: 253_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(08)60729-1 contributor: fullname: JE Damber – volume: 26 start-page: 1148 year: 2008 ident: 253_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.4487 contributor: fullname: HI Scher – volume: 369 start-page: 213 year: 2013 ident: 253_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa1213755 contributor: fullname: C Parker – volume: 324 start-page: 787 year: 2009 ident: 253_CR15 publication-title: Science doi: 10.1126/science.1168175 contributor: fullname: C Tran – volume: 363 start-page: 411 year: 2010 ident: 253_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa1001294 contributor: fullname: PW Kantoff |
SSID | ssj0017856 |
Score | 2.1894264 |
Snippet | The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with... Background The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with... BACKGROUNDThe aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with... |
SourceID | pubmedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 63 |
SubjectTerms | Aged Aged, 80 and over Androgens Antineoplastic Agents - administration & dosage Asian People Cancer therapies Care and treatment Chemotherapy Clinical trials Complications and side effects Docetaxel Dosage and administration Drug Administration Schedule Drug therapy Feasibility Studies Humans Intravenous administration Male Medical prognosis Medical records Metastases Metastasis Middle Aged Neoplasm Metastasis Patients Prednisolone Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Retrospective Studies Taxoids - administration & dosage Toxicity Treatment Outcome Urology Working groups |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9RAEB60BfFF_N1olRUEQRrabHY3yZOc0lKEFhELfVuS3Vk80OR6SdH2X-g_7Uxu72x88HknXC4zO_PtzM43AG8VKtQhc2S8BN-UVI4TTXTmMbqpa6eCbDihf3Jqjs_U53N9HhNufbxWufaJo6P2neMc-T4BDab-MpX6sLhIeWoUV1fjCI27sC0zxWXa7Y-Hp1--buoIRalNrGVmpdnvyRszFS55Zor1eXo9iUb_-uRbQWl6YfJWBDp6CA8idBSzla4fwR1sH8O9k1gcfwI3M7HEYdmtmydFwDpefr0SI42s6IJo5r9GEv09EvakV5_6rkdBHwCH-jf-EPNWzLizUkTK1V5wrla4emTYxZTO54w522FP_KRHuCNp7sSCu0domeTIjJZP4ezo8Nun4zTOWkidqtSQKp8HHlRVBiaIR6MlVvWBV4VvKMCHQEimkMwtH7wrpPa-ynMZGlUhRbvM1_kz2Gq7FndAoDnwsmLcoQrVSNrwpfIZYk7G4n3wCbxff3O7WFFq2PEoUhq7UpAlBVlWkL1O4B1rxfJ2o3_p6tg1QD_FxFV2xoCxIEymE9idSNI2cdPltV5t3Ka9_WtUCbzZLPOTfPWsxe5ylGFKoTIvE3i-MoPNa_OoZnKBMoFiYiAbASbvnq608-8jibfWpiAs9uL_r_US7svRWsmdyV3YGpaX-IpQ0NC8jqb-B-IkCqY priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9VAEB5qBfGl1Hu0ygqCII32bGazyUORg1iKcHzyQN-WJLuLB9qk5qT08hf8085skmMjxeedXOfbuezufAPwDh065WcVgZfCN5RY8UIT5TypKouiQi9LXtBffE-Pl_jtRJ1swdjeaviB6ztTO-4ntWxPP179uv5ME_4wTPgs_bQmG8sEt2RvyYMn8c09uC8xQQb8Av9uKuhM9cVGehZT1jFuct55i4mb-tdY3_JW05OUt1zT0S7sDDGlmPcgeARbrn4MDxbDrvkT-D0XrevaZqyqFN4Vw6nYaxH4ZUXjRbm6DOz6-yRsSeE2ts3aCUsOriuu3KlY1WLOJZdi4GJdC17EFVURqHddTIk7B6N1ty_O6BIuVVpV4pzLSmiY5Ahf7VNYHn398eU4HpowxBXm2MVoE88drDLPzPEuVdLlxYFFbUvy_N5TiKMlk857W2mprM2TRPoSc0ducGaL5Bls103tXoBw6YGVOQckqLGUZAkytDPnEkKRtd5G8GH85-a859owIUfJUtMryJCCDCvI3ETwnrViGBn0lVUxlBPQo5jRysw5ktQUrKkI9iaSNH-q6fCoVzPCz1BYy0RzaY4RvN0M85V8Jq12zUWQYa6hLMkieN7DYPPa3MOZbKOMQE8AshFgVu_pSL36Gdi9lUo1BWkv___Wr-ChDGglOyf3YLtrL9xrCo-68k0A_R_X1A4G priority: 102 providerName: Scholars Portal |
Title | A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28830482 https://www.proquest.com/docview/1934654694 https://www.proquest.com/docview/1931716838/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC5567901 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJCqWX0nedposKhUKJs1lZsuTjJiSEwoYQGlh6EbYe1JC1l12HpvkL_dOd0cpL3GMvvmiEH_ONZkaa-UzIZ-64E35iALwQvnHGDW40Qc6Ti6osDfeswg392WV-ccO_zcV8h4i-FyYU7ZuqPmpuF0dN_TPUVi4XZtzXiY2vZqdC5BL82HiX7Mos61P0eHQglcjj8eVE5eM1LMDIfguLMbj3LH1A-l-lIItXbOCL_l2RH7mkYbnkI_9z_oI8j4EjnW4e8CXZcc0r8nQWj8Zfkz9TunLdqu1bJ6l3ZSx9_U0DiSxtPa3qX4FC_xCELWjVprZdO2rBi3XlvbuldUOn2FdJI-HqmuJOLTVl4Nd1KWTnGHE23SFdwBTsR6oNXWLvCAyDHIBo9YbcnJ99P71I458WUsML3qXcZh5_U6U80sO7XDBXlMeWS1uBe_ce4hjJkFneWyOZsLbIMuYrXjjwdRNbZm_JXtM27j2hLj-2rMCog0teMTB3xe3EuQygYq23Cfnaf3O93BBq6JCIqFxvdKVBVxp1pR8S8gW1otHY4C1NGXsG4FZIW6WnGC5KiMhEQg4GkmAkZjjc61VHI11riF2RTS4veEI-bYdxJhaeNa69CzJIKKQylZB3GxhsH7uHUULkACBbAaTuHo4AogOFd0Tw_n_P_ECesYBpWOfYAdnrVnfuI4RHXTUCo5jLEXlycnZ5dT0KmwxwnXEF1-uTH6NgLn8B-c0XjQ |
link.rule.ids | 230,315,733,786,790,870,891,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkYAL4k2ggJGQkFCjdm3ndUIrRLVAt6dW2puV2GOxEiTLJhXQv8CfZsbrXRoOnD1RnMx45vPY8w3Aa40aMz-xZLwE37TUlhNNtOfJs6aurfay4YT-_DSfnetPi2wRE259vFa59YnBUbvOco78kIAGU3_llX63-p5y1yg-XY0tNK7DDa2UZjsvFrsNFzeez-NJ5qTMD3vyxUyES36ZIr1KL0ex6F-PfCUkja9LXok_x3fhTgSOYrrR9D24hu19uDmPR-MP4PdUrHFYd9vSSeGxjldff4lAIis6L5rlj0Chf0DCjrTqUtf1KOjzcah_4lexbMWU6ypFJFztBWdqha0Dvy6mtDtnxNkOB-IbPcL1SEsrVlw7QsMkR0a0fgjnxx_O3s_S2GkhtbrSQ6qd8tymqvRMD495JrGqj5wuXEPh3XvCMYVkZnnvbCEz5yqlpG90hRTrJq5Wj2Cv7Vp8AgLzIycrRh260I2k5V5qN0FUZCrOeZfA2-0_N6sNoYYJG5EyNxsFGVKQYQWZywTesFYMLzb6SlvHmgF6FdNWmSnDxYIQWZbA_kiSFokdD2_1auIi7c1fk0rg1W6Yn-SLZy12F0GGCYVKVSbweGMGu2lzo2ZygDKBYmQgOwGm7h6PtMsvgcI7y_KCkNjT_0_rJdyanc1PzMnH08_P4LYMlkuOTe7D3rC-wOeEh4bmRTD6PxNfDC0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBWX8oaUAkZCQkLNpus4iXNcFVblsVUPVKq4WIkfIqKbrJKsgP0L_GlmEme16bFnj5VE-Wbmsz3zmZB33HAT2akC8AJ944wr3GiCNU8c5VmmuGU5bugvzuOzS_7lKrraueqrK9pXeTEpr5eTsvjZ1VaulioY6sSCi8VpFMUJ5LFgpW1wl9wDn2XJsFB3BwiJiGJ3iDkVcdBAGEYNXAjJkORDf4MiwELAWl6wUUa6GZd3EtO4aHInC80fkB_D-_fFJ78m6zafqM0NacdbfeBDcuC4KZ31Jo_IHVM-JvsLd_r-hPyb0dq0dTV0Z1JrMldd-5d2OrW0sjQvfncq_cdgrAE42tdVY6iGRNlmf8w1LUo6w9ZN6jRdG4qbwVRlnYSv8WvTIKkt22O6hCnY8lQousL2FBgGO8Bp_ZRczj99Pz3z3WUOvuIpb32uQ4s3YQmLCvQmjphJsxPNE50Dg7AWqFLCULzeapWwSOs0DJnNeWognU51Fj4je2VVmheEmvhEsxSJDU94ziCiCK6nxoSARq2t9siH4YfKVa_ZIbu1johlDwQJQJAIBLnxyHv85RL9Gb5SZa4tAR6Fylhyhow0AdIXeeRoZAl-qMbDA2ikiwONBHqMgnVxyj3ydjuMM7G2rTTVurNBzSIRCo887zG2fe0Box5JRujbGqA6-HgEMNWphDsMHd565huyf_FxLr99Pv_6ktxnne9AVGVHZK-t1-YVkLE2f9253X_gVDal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+retrospective+feasibility+study+of+biweekly%2C+reduced-dose+docetaxel+in+Asian+patients+with+castrate-resistant%2C+metastatic+prostate+cancer&rft.jtitle=BMC+urology&rft.au=Kim%2C+Hae+Su&rft.au=Lee%2C+Ji+Yun&rft.au=Lee%2C+Su+Jin&rft.au=Lim%2C+Ho+Yeong&rft.date=2017-08-22&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2490&rft.eissn=1471-2490&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1186%2Fs12894-017-0253-z&rft.externalDocID=A511271595 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2490&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2490&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2490&client=summon |